Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07876856
PHASE1/PHASE2

A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB)

Sponsor: Ausper Biopharma Co., Ltd.

View on ClinicalTrials.gov

Summary

This is a study of sequential therapy with AHB-137 injection followed by TVAX-008 injection in participants living with Chronic Hepatitis B (CHB).

Official title: A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 1/2 Study to Evaluate AHB-137 Injection Followed by TVAX-008 Injection in Participants With HBeAg-Negative Chronic Hepatitis B Treated With Nucleos(t)Ide Analogs

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

105

Start Date

2026-10-31

Completion Date

2029-06-20

Last Updated

2026-10-19

Healthy Volunteers

No

Interventions

DRUG

AHB-137

AHB-137 will be administered per 1 week.

DRUG

Placebo

Placebo will be used per 4 weeks.

DRUG

TVAX-008

TVAV-008 will be administered per 4 weeks.